MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5306/wjco.v11.i7.504

Медицинская библиотека · World journal of clinical oncology · 2020

Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report.

Ozaki Yuri, Yoshimura Akiyo, Sawaki Masataka, Hattori Masaya, Gondo Naomi, Kotani Haruru, Adachi Yayoi, Kataoka Ayumi, Sugino Kayoko, Horisawa Nanae, Endo Yuka, Nozawa Kazuki, Sakamoto Shoko, Iwata Hiroji

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Bevacizumab is an antiangiogenic agent, and that synergizes with chemotherapeutic drugs. When used in combination therapies, Bevacizumab is associated with adverse events such as hemorrhage, gastrointestinal perforation, delayed wound healing, and pneumothorax. However, the molecular mechanisms underlying these adverse events are not fully understood.

CASE SUMMARY: A 45-year-old female with multiple lung metastases that were derived from primary breast cancer, was placed on Bevacizumab + paclitaxel therapy, since this combination has a potent antitumor effect. She reported dyspnea before cycle 3, day 1 and we therefore ran a chest X-ray, which detected a right pneumothorax. The coronal plane computed tomography revealed that one solid mass rapidly necrosed and was replaced by a cavity that passed through the bronchus in the right lower lobe. The cavity eventually ruptured the pleura and made the bronchopleural fistula that led to this pneumothorax. Thoracic cavity drainage using an intercostal catheter was performed. On the 7th day of drainage, the patient was discharged from our hospital on recovery. Recurrence of pneumothorax was not reported, and continuation of chemotherapy was made possible by changing the regimen.

CONCLUSION

Patients with lung metastases surrounding the bronchi and on the pleura should be monitored for pneumothorax by Bevacizumab-containing chemotherapies.

Для цитирования: Ozaki Yuri, Yoshimura Akiyo, Sawaki Masataka, Hattori Masaya, Gondo Naomi, Kotani Haruru, Adachi Yayoi, Kataoka Ayumi, Sugino Kayoko, Horisawa Nanae, Endo Yuka, Nozawa Kazuki, Sakamoto Shoko, Iwata Hiroji. Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report.. World journal of clinical oncology. 2020. DOI: 10.5306/wjco.v11.i7.504.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.